Načítá se...
Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
Fostamatinib demonstrated efficacy in phase 3 trials of adults with immune thrombocytopenia (ITP). Post hoc analysis compared patients who received fostamatinib as second‐line therapy (after steroids ± immunoglobulins) versus third‐or‐later‐line therapy (after ≥2 prior lines of therapy including a s...
Uloženo v:
| Vydáno v: | Br J Haematol |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7540289/ https://ncbi.nlm.nih.gov/pubmed/33439486 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16959 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|